๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C

โœ Scribed by Pietro Andreone; Carmela Cursaro; Annagiulia Gramenzi; Andrea Buzzi; Maria Grazia Covarelli; Loriana Di Giammarino; Rita Miniero; Vincenzo Arienti; Mauro Bernardi; Giovanni Gasbarrini

Book ID
114796991
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
365 KB
Volume
16
Category
Article
ISSN
0106-9543

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Thymosin treatment of chronic hepatitis
Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial
โœ Milton G. Mutchnick; Henry D. Appelman; H. T. Chung; Emma Aragona; Tej P. Gupta; ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 828 KB

Chronic hepatitis B is a severe and frequently progressive disease. We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liv

Combination therapy with thymosin ฮฑ1 and
Combination therapy with thymosin ฮฑ1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
โœ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 111 KB ๐Ÿ‘ 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin โฃ1 (TA1), an immunomodulatory peptide, to the standard tr